MedTrace Logo

Phase 1 Study of DHP2302R1 and DHP2302R2 in Healthy Adult Volunteers

NCT06318845 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-07-25

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and drug interaction of DHP2302R1 and DHP2302R2 when administered alone versus in combination in healthy South Korean adult participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

DHP2302R1

75 mg per dose, once daily

DRUG

DHP2302R2

50 mg per dose, once daily

Sponsors & Collaborators

  • Daehwa Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-04
Primary Completion
2024-04-26
Completion
2024-05-07

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06318845 on ClinicalTrials.gov